Patents by Inventor Lan Bo Chen

Lan Bo Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11628210
    Abstract: An isolated nucleic acid that contains a nucleotide sequence that encodes the polypeptide of SEQ ID NO: 3. The polypeptide of SEQ ID NO: 3 specifically binds to stage-specific embryonic antigen 4 (SSEA4). Also disclosed is a recombinant cell comprising the isolated nucleic acid described above, a viral vector containing the above isolated nucleic acid, and an isolated polypeptide including the sequence of SEQ ID NO: 3. Provided as well is a chimeric antigen receptor (CAR) that includes a single chain Fv having the sequence of SEQ ID NO: 3 and specifically binding to SSEA4. Moreover, a method is disclosed for treating a tumor by transducing in vitro the T cells of a subject having a tumor expressing SSEA4 with a vector that encodes the CAR, expanding the transduced T cells, and infusing the expanded transduced T cells into the subject, whereby an anti-tumor T cell response is raised.
    Type: Grant
    Filed: July 17, 2020
    Date of Patent: April 18, 2023
    Assignee: CHO Pharma USA, Inc.
    Inventor: Lan Bo Chen
  • Patent number: 11446379
    Abstract: A nucleic acid construct that encodes a monoclonal antibody or antigen-binding fragment that specifically binds to stage-specific embryonic antigen 4. The monoclonal antibody or antigen-binding fragment includes a heavy-chain CDR1 having the sequence of SEQ ID NO: 33 or SEQ ID NO: 40, a heavy-chain CDR2 having the sequence of SEQ ID NO: 34 or SEQ ID NO: 39, a heavy-chain CDR3 having the sequence of SEQ ID NO: 35 or SEQ ID NO: 41, a light-chain CDR1 having the sequence of SEQ ID NO: 36 or SEQ ID NO: 42, a light-chain CDR2 having the sequence of SEQ ID NO: 37 or SEQ ID NO: 43, and a light-chain CDR3 having the sequence of SEQ ID NO: 38 or SEQ ID NO: 44. Also disclosed are recombinant cells containing the nucleic acid construct.
    Type: Grant
    Filed: May 15, 2020
    Date of Patent: September 20, 2022
    Assignee: CHO Pharma USA, Inc.
    Inventor: Lan Bo Chen
  • Publication number: 20200338177
    Abstract: An isolated nucleic acid that contains a nucleotide sequence that encodes the polypeptide of SEQ ID NO: 3. The polypeptide of SEQ ID NO: 3 specifically binds to stage-specific embryonic antigen 4 (SSEA4). Also disclosed is a recombinant cell comprising the isolated nucleic acid described above, a viral vector containing the above isolated nucleic acid, and an isolated polypeptide including the sequence of SEQ ID NO: 3. Provided as well is a chimeric antigen receptor (CAR) that includes a single chain Fv having the sequence of SEQ ID NO: 3 and specifically binding to SSEA4. Moreover, a method is disclosed for treating a tumor by transducing in vitro the T cells of a subject having a tumor expressing SSEA4 with a vector that encodes the CAR, expanding the transduced T cells, and infusing the expanded transduced T cells into the subject, whereby an anti-tumor T cell response is raised.
    Type: Application
    Filed: July 17, 2020
    Publication date: October 29, 2020
    Inventor: Lan Bo Chen
  • Publication number: 20200276308
    Abstract: A nucleic acid construct that encodes a monoclonal antibody or antigen-binding fragment that specifically binds to stage-specific embryonic antigen 4. The monoclonal antibody or antigen-binding fragment includes a heavy-chain CDR1 having the sequence of SEQ ID NO: 33 or SEQ ID NO: 40, a heavy-chain CDR2 having the sequence of SEQ ID NO: 34 or SEQ ID NO: 39, a heavy-chain CDR3 having the sequence of SEQ ID NO: 35 or SEQ ID NO: 41, a light-chain CDR1 having the sequence of SEQ ID NO: 36 or SEQ ID NO: 42, a light-chain CDR2 having the sequence of SEQ ID NO: 37 or SEQ ID NO: 43, and a light-chain CDR3 having the sequence of SEQ ID NO: 38 or SEQ ID NO: 44. Also disclosed are recombinant cells containing the nucleic acid construct.
    Type: Application
    Filed: May 15, 2020
    Publication date: September 3, 2020
    Inventor: Lan Bo Chen
  • Patent number: 10751399
    Abstract: An isolated nucleic acid that contains a nucleotide sequence that encodes the polypeptide of SEQ ID NO: 3. The polypeptide of SEQ ID NO: 3 specifically binds to stage-specific embryonic antigen 4 (SSEA4). Also disclosed is a recombinant cell comprising the isolated nucleic acid described above, a viral vector containing the above isolated nucleic acid, and an isolated polypeptide including the sequence of SEQ ID NO: 3. Provided as well is a chimeric antigen receptor (CAR) that includes a single chain Fv having the sequence of SEQ ID NO: 3 and specifically binding to SSEA4. Moreover, a method is disclosed for treating a tumor by transducing in vitro the T cells of a subject having a tumor expressing SSEA4 with a vector that encodes the CAR, expanding the transduced T cells, and infusing the expanded transduced T cells into the subject, whereby an anti-tumor T cell response is raised.
    Type: Grant
    Filed: March 20, 2018
    Date of Patent: August 25, 2020
    Assignee: CHO Pharma USA, Inc.
    Inventor: Lan Bo Chen
  • Patent number: 10688182
    Abstract: An isolated monoclonal antibody or antigen-binding fragment that specifically binds to stage-specific embryonic antigen 4. The monoclonal antibody or antigen-binding fragment includes a heavy-chain CDR1 having the sequence of SEQ ID NO: 33 or SEQ ID NO: 40, a heavy-chain CDR2 having the sequence of SEQ ID NO: 34 or SEQ ID NO: 39, a heavy-chain CDR3 having the sequence of SEQ ID NO: 35 or SEQ ID NO: 41, a light-chain CDR1 having the sequence of SEQ ID NO: 36 or SEQ ID NO: 42, a light-chain CDR2 having the sequence of SEQ ID NO: 37 or SEQ ID NO: 43, and a light-chain CDR3 having the sequence of SEQ ID NO: 38 or SEQ ID NO: 44. Also disclosed is an anti-tumor method carried out by administering the above monoclonal antibody or antigen-binding fragment to a subject having a tumor that expresses stage-specific embryonic antigen 4. Further provided are nucleic acids encoding the above sequences and recombinant cells containing the nucleic acids.
    Type: Grant
    Filed: March 29, 2018
    Date of Patent: June 23, 2020
    Assignee: CHO Pharma USA, Inc.
    Inventor: Lan Bo Chen
  • Publication number: 20200138748
    Abstract: Disclosed is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release diphenhydramine HCl and a sleep aid in sequence at two stages.
    Type: Application
    Filed: November 6, 2018
    Publication date: May 7, 2020
    Applicant: Sequential Medicine Limited
    Inventor: Lan Bo CHEN
  • Publication number: 20190298828
    Abstract: An isolated monoclonal antibody or antigen-binding fragment that specifically binds to stage-specific embryonic antigen 4. The monoclonal antibody or antigen-binding fragment includes a heavy-chain CDR1 having the sequence of SEQ ID NO: 33 or SEQ ID NO: 40, a heavy-chain CDR2 having the sequence of SEQ ID NO: 34 or SEQ ID NO: 39, a heavy-chain CDR3 having the sequence of SEQ ID NO: 35 or SEQ ID NO: 41, a light-chain CDR1 having the sequence of SEQ ID NO: 36 or SEQ ID NO: 42, a light-chain CDR2 having the sequence of SEQ ID NO: 37 or SEQ ID NO: 43, and a light-chain CDR3 having the sequence of SEQ ID NO: 38 or SEQ ID NO: 44. Also disclosed is an anti-tumor method carried out by administering the above monoclonal antibody or antigen-binding fragment to a subject having a tumor that expresses stage-specific embryonic antigen 4. Further provided are nucleic acids encoding the above sequences and recombinant cells containing the nucleic acids.
    Type: Application
    Filed: March 29, 2018
    Publication date: October 3, 2019
    Inventor: Lan Bo Chen
  • Publication number: 20190290744
    Abstract: An isolated nucleic acid that contains a nucleotide sequence that encodes the polypeptide of SEQ ID NO: 3. The polypeptide of SEQ ID NO: 3 specifically binds to stage-specific embryonic antigen 4 (SSEA4). Also disclosed is a recombinant cell comprising the isolated nucleic acid described above, a viral vector containing the above isolated nucleic acid, and an isolated polypeptide including the sequence of SEQ ID NO: 3. Provided as well is a chimeric antigen receptor (CAR) that includes a single chain Fv having the sequence of SEQ ID NO: 3 and specifically binding to SSEA4. Moreover, a method is disclosed for treating a tumor by transducing in vitro the T cells of a subject having a tumor expressing SSEA4 with a vector that encodes the CAR, expanding the transduced T cells, and infusing the expanded transduced T cells into the subject, whereby an anti-tumor T cell response is raised.
    Type: Application
    Filed: March 20, 2018
    Publication date: September 26, 2019
    Inventor: Lan Bo Chen
  • Publication number: 20180028633
    Abstract: A method for treating a tumor in a subject by administering at least three of the following treatment modalities: (i) an antibody, (ii) T cells bearing a first chimeric antigen receptor (CAR), (iii) NK cells bearing a second CAR, and (iv) NKT cells bearing a third CAR. The antibody binds specifically to stage-specific embryonic antigen 4 and each CAR contains a scFv that also binds specifically to SSEA4.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 1, 2018
    Inventor: Lan Bo Chen
  • Publication number: 20180028634
    Abstract: A method for treating a tumor includes administering (i) a vaccine that contains stage-specific embryonic antigen 4 conjugated to a carrier, (ii) an antibody that binds specifically to SSEA-4, and (iii) immune cells expressing a chimeric antigen receptor that specifically binds to SSEA-4. The tumor, which expresses SSEA-4, can be a breast, colon, gastrointestinal, kidney, lung, liver, ovarian, pancreatic, rectal, stomach, testicular, thymic, cervical, prostate, bladder, skin, nasopharyngeal, esophageal, oral, head and neck, bone, cartilage, muscle, lymph node, bone marrow, or brain tumor.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 1, 2018
    Inventor: Lan Bo Chen
  • Publication number: 20180030124
    Abstract: A method for treating a tumor by administering an antibody or antibody fragment that binds specifically to stage-specific embryonic antigen 4, and an agent that enhances T cell anti-tumor responses. Also provided is a pharmaceutical composition for treating a tumor. The pharmaceutical composition contains an anti-SSEA4 antibody or antibody fragment, an agent that enhances T cell responses, and a pharmaceutically acceptable excipient.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 1, 2018
    Inventor: Lan Bo Chen
  • Publication number: 20180028632
    Abstract: Two methods for treating a tumor are disclosed. The first method includes (i) obtaining NK cells or NKT cells from a subject, (ii) transducing the NK cells or NKT cells in vitro with an expression vector encoding a chimeric antigen receptor that contains an scFv specifically recognizing stage-specific embryonic antigen 4, (iii) expanding the transduced NK cells or NKT cells in vitro, and (iv) infusing the expanded transduced NK cells or NKT cells into the subject. The second method includes, in place of step (ii) above, transducing the NK cells or NKT cells in vitro with an expression vector encoding a chimeric antigen receptor that is specific for a tumor antigen other than stage-specific embryonic antigen 4, and further requires a step of administering an antibody against stage-specific embryonic antigen 4.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 1, 2018
    Inventor: Lan Bo Chen
  • Publication number: 20180028631
    Abstract: A chimeric antigen receptor containing (i) a single chain Fv that specifically binds to stage-specific embryonic antigen 4 and (ii) an endodomain from CD3? or Fc?RI?. Also provided is a nucleic acid encoding the chimeric antigen receptor and an expression vector that contains the nucleic acid operably linked to a promoter that is active in T cells. Furthermore, two similar methods for treating a tumor are disclosed. The first method includes (i) obtaining T cells from a subject, (ii) transducing the T cells in vitro with an expression vector encoding a chimeric antigen receptor that contains an scFv specifically recognizing stage-specific embryonic antigen 4, (iii) expanding the transduced T cells in vitro, and (iv) infusing the expanded transduced T cells into the subject.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 1, 2018
    Inventor: Lan Bo Chen
  • Publication number: 20180028630
    Abstract: An immunogenic composition that includes a glycoconjugate containing a fusion protein composed of an immunoglobulin gamma Fc domain fused to a tumor-associated antigen, the fusion protein being cross-linked to an azido-modified stage-specific embryonic antigen 4 conjugated to diphtheria toxoid cross-reactive material 197; and ?-galactosylceramide C34 or ?-glucosylceramide C34. Also provided are methods for treating cancer by administering the immunogenic composition to a patient.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 1, 2018
    Inventor: Lan Bo Chen
  • Publication number: 20180030123
    Abstract: A method for treating a tumor with at least two bifunctional agents. The bifunctional agents each include a binding domain that specifically binds to stage-specific embryonic antigen 4 (SSEA4) or an SSEA4 analog, and an effector domain selected from a cytokine, a cytotoxic agent, an immunoglobulin Fc domain, anti-CD3, and anti-CD16.
    Type: Application
    Filed: July 31, 2017
    Publication date: February 1, 2018
    Inventor: Lan Bo Chen
  • Publication number: 20160346216
    Abstract: Described is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release a compound or combination of compounds in sequence at multiple stages.
    Type: Application
    Filed: August 11, 2016
    Publication date: December 1, 2016
    Inventor: Lan Bo Chen
  • Patent number: 9427409
    Abstract: Described is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release a compound or combination of compounds in sequence at multiple stages.
    Type: Grant
    Filed: February 5, 2015
    Date of Patent: August 30, 2016
    Assignee: Sequential Medicine Limited
    Inventor: Lan Bo Chen
  • Publication number: 20150216811
    Abstract: Described is a controlled-release formulation for treating disturbed sleep or insomnia in a subject. The formulation is formulated to release a compound or combination of compounds in sequence at multiple stages.
    Type: Application
    Filed: February 5, 2015
    Publication date: August 6, 2015
    Inventor: Lan Bo Chen
  • Patent number: 8071294
    Abstract: The present invention relates to compositions and methods for sensitizing cancer therapy. The invention provides such compositions comprising a SPARC family polypeptide or polynucleotide, as well as recombinant cells containing a SPARC family polypeptide or polynucleotide. The compositions and methods of the invention are useful in in vitro study of cancer therapy resistance, as well as ex vivo and in vivo therapy of cancer.
    Type: Grant
    Filed: November 25, 2009
    Date of Patent: December 6, 2011
    Assignee: Dana-Farber Cancer Institute
    Inventors: Isabella T. Tai, Lan Bo Chen